Commentary · 21 Feb 2026
Conference abstractPublished 26 Sep 2016
NRF2-mediated changes in glutathione metabolism mediate the resistance of EGFR-T790M mutant lung cancer cells to Erlotinib
Imperial College London, UK Wuhan Institute of Physic and Mathematics, China Signal Transduction Laboratory, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
EGFR tyrosine-kinase inhibitors (TKI) such as erlotinib are novel agents in the treatment of lung cancer. However, their efficacy is impaired by the development of drug-resistance through secondary receptor mutations (e g. T790M). Although decreased affinity of the mutants for the inhibitors was considered responsible for this, we show that additional factors are at play. Following metabonomics profiling of erlotinib-sensitive/resistant cell pairs, we found that the levels of glutathione (GSH) are considerably reduced in erlotinib-resistant (ER) cells. Using RNA interference and pharmacological inhibitors of GSH pathway enzymes, we demonstrated that increasing GSH levels in ER cells sensitizes these to erlotinib. Conversely, reducing GSH levels renders sensitive cells resistant to the drug. We show that the reduction in GSH levels in ER cells is associated with the decreased transcription of the GSH synthesizing enzymes, GCLC and GSS. This correlates with inhibition of NRF2, through increased KEAP1 levels and/or decreased expression of SQSTM1 and PALB2. We demonstrate these changes to be directly linked to the T790M-EGFR mutation, as introducing this mutant in HEK293 cells reduces GSH levels and decreases expression of SQSTM1 and PALB2. Finally, administration of ethacrynic acid, a GST inhibitor that increases intracellular GSH levels, re-sensitizes resistant tumors to erlotinib in a xenograft mouse model. Our data identify a new resistance mechanism to EGFR TKIs and propose a novel therapeutic strategy to tackle this problem in the clinic.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Olivier E Pardo”
- BylineArticles whose byline prints “William B Stokes”
- BylineArticles whose byline prints “Hongde Li”
- BylineArticles whose byline prints “Emily Chater”
- BylineArticles whose byline prints “Rajat Roy”
- BylineArticles whose byline prints “Elza De Bruin”
- BylineArticles whose byline prints “Julian Downward”
- BylineArticles whose byline prints “Michael J Seckl”
